In a previously mentioned meta-analysis, including, in this case, the four cardiovascular outcome trials with GLP-1 receptor agonists available at the end of 2018, this class of drugs was associated with a 13% reduction in the risk for non-fatal stroke, even if atherothrombotic, thromboembolic, and/or hemorrhagic events were not differentiated [46]. The gene discussed is GLP1R; the disease is stroke disorder.